Argentus Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
Sell
-473
Closed -$38K 278
2016
Q3
$38K Buy
473
+42
+10% +$3.36K 0.01% 460
2016
Q2
$34K Buy
431
+25
+6% +$1.88K 0.01% 464
2016
Q1
$29K Buy
406
+91
+29% +$6.89K 0.01% 471
2015
Q4
$27K Sell
315
-4,530
-93% -$376K 0.01% 436
2015
Q3
$405K Sell
4,845
-10,684
-69% -$902K 0.06% 273
2015
Q2
$1.3M Sell
15,529
-316
-2% -$24.1K 0.2% 140
2015
Q1
$1.15M Sell
15,845
-61
-0.4% -$4.34K 0.18% 163
2014
Q4
$1.1M Buy
15,906
+2,790
+21% +$188K 0.18% 158
2014
Q3
$851K Buy
13,116
+679
+5% +$43K 0.14% 191
2014
Q2
$773K Buy
12,437
+611
+5% +$36.5K 0.2% 116
2014
Q1
$696K Buy
11,826
+391
+3% +$21.8K 0.17% 111
2013
Q4
$583K Buy
+11,435
New +$573K 0.12% 127

Other funds holding LLY

Argentus Capital Management's LLY Position: Q4 2016 in Review

Argentus Capital Management sold out of Eli Lilly (LLY) in Q4 2016, closing a stake of 473 shares — an estimated $38K sold.

Argentus Capital Management first reported a position in LLY in Q4 2013 and held it in 12 quarters. The position peaked at $1.3M in Q2 2015. 1,212 funds tracked by Wall St. Rank hold LLY as of Q4 2016.

  • Argentus Capital Management reported no remaining Eli Lilly position as of Q4 2016 after selling out during the quarter.
  • Argentus Capital Management sold 473 Eli Lilly shares in Q4 2016, an estimated $38K.
  • Argentus Capital Management first reported a position in Eli Lilly in Q4 2013 and held it in 12 quarters.
  • Argentus Capital Management's Eli Lilly position peaked at $1.3M in Q2 2015.
  • 1,212 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2016.

Based on Argentus Capital Management's 13F filing for Q4 2016.